Please use this identifier to cite or link to this item:
|Title:||Overview of the study protocols and statistical analysis plan for the Saline versus Plasma-Lyte 148 for Intravenous Fluid Therapy (SPLIT) research program.|
|Authors:||Reddy, Sumeet K;Young, Paul J;Beasley, Richard W;Mackle, Diane M;McGuinness, Shay P;McArthur, Colin J;Henderson, Seton J;Weinberg, Laurence;French, Craig J;Orford, Neil R;Bailey, Michael J;Bellomo, Rinaldo|
|Affiliation:||Medical Research Institute of New Zealand, Wellington, New Zealand. firstname.lastname@example.org.|
Medical Research Institute of New Zealand, Wellington, New Zealand.
Department of Anaesthesia, Austin Hospital, Melbourne, VIC, Australia.
Intensive Care Unit, The Western Hospital, Melbourne, VIC, Australia.
Intensive Care Unit, Geelong Hospital, Geelong, VIC, Australia.
Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, VIC, Australia.
Intensive Care Unit, Wellington Hospital, Wellington, New Zealand.
|Citation:||Critical Care and Resuscitation : Journal of the Australasian Academy of Critical Care Medicine; 17(1): 29-36|
|Abstract:||0.9% saline is the most commonly used intravenous (IV) fluid in the world but recent data raise the possibility that, compared with buffered crystalloid fluids such as Plasma-Lyte 148, the administration of 0.9% saline might increase the risk of developing acute kidney injury.To provide an overview of the study protocols and statistical analysis plan for the six studies making up the (0.9% Saline v Plasma-Lyte 148 for Intravenous Fluid Therapy (SPLIT) research program.The SPLIT study consists of six integrated clinical trials, including a double-blind, cluster, randomised, double-crossover study in intensive care unit patients, incorporating two nested studies within it; an open-label, before-and-after study in emergency department (ED) patients; a single-centre, double-blind, crossover trial in major surgical patients; and a randomised, double-blind study in ICU patients. All studies focus on biochemical and renal outcomes but will also provide preliminary data on patient-centred outcomes including inhospital mortality and requirements for dialysis.The SPLIT study program will provide preliminary data on the comparative effectiveness of using 0.9% saline v Plasma-Lyte 148 for IV fluid therapy in ED, surgical and ICU patients.|
|Internal ID Number:||25702759|
|Subjects:||Acute Kidney Injury.etiology|
Gluconates.administration & dosage
Magnesium Chloride.administration & dosage
Potassium Chloride.administration & dosage
Randomized Controlled Trials as Topic
Sodium Acetate.administration & dosage
Sodium Chloride.administration & dosage.adverse effects
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.